one i just asked biogen, same thing. tax rate will go down so presumably free cash flow will go up. will you begin paying a dividend and especially with michigan and our viewers know, michigan's a state close to our heart. we go there a lot. what are your hiring plans? >> so we do have a dividend, a very small dividend. >> fractional. >> it admittedly is small. we are looking at utilizing our cash and we have a cash process, where we are looking at what can we do for additional acquisition. in my seven years, we have done about 17 acquisitions. we think there is still good opportunities to bolt on another product category and bringing on the truck that we send to our next customer, whatever large retailer it may be. on the issue of hiring, we still have big plans for hiring both here in the united states but also in dublin as we now recognize that as our global headquarters. >> joe papa, a pleasure. thank you very much for joining us here on cnbc. i know you have been with jim cramer on "mad money." he likes perrigo and has been right. you're up over 55% over 12 months. have a great

they've taken him out of the biog biogen sis lawsuit. i can't for the life of me under league baseball could look themselves in the mirror and do this. they've agreed to go to federal prosecutors and ask that bosch be given lenience in an investigation where bosch is investigated and will be charged with dishing out steroids to children in south florida. >> in my heart, i suspect a-rod lied before. he lied to katie couric in an interview. i suspect something's up here. that's my gut after reading everything i can read about the case. my take is major league baseball has known for years, you go back to sammy sosa, barry bonds. everybody knew these guys were using it. major league baseball turned a blind eye. do you agree with that? >> oh, absolutely. capsizes were going from 7 to 7 5/8. barry bonds' head tripled in size. people hitting five home runs were hitting 40. sammy sosa, they went to his house in the dominican republic. >> if major league baseball wants to get rid of these drugs, three have a means of doing that, drug tests. and a

pdl pharma, it's not biogen, regeneron, celgene, gilead. it's a nice spec.e when i recommended. i'm not keen on tobacco. at&t and verizon. we can't have both of these. that's not going to work. i know you want some yield and you feel like yield should be the thing here. i'm going to send you to another stock that was downgraded today. clorox. and that, ladies and gentlemen, is another round of am i diversified. >>> after the close one of my bankable 21 ceos from macy's reported a number that was really good and sent the stock up after hours. i like macy's. just for you right here on "mad money." i'm jim cramer and i will see you tomorrow! [ helicopter blades whirring ] [ sea gulls squawking ] [ indistinct shouting ]

especially biogen-idec. plenty of people with big gains who didn't sell today. they will most likely take profits tomorrow. these themes could be more of a day three or day four consideration. day three is good for the regionals which are terrific to date. they were brought down by the etfs that handle the financials and take everything down equally. i also like many of the special situation plays. dow chemical and maybe ebay now that they are under new activist pressures. the terrifically performing techs like telco equipment stocks, i want them, but they have china exposure. normally you don't want to be aggressive on day three. because you don't know which ones actually have indirect exposure to china. the day four stocks will still be regarded as sales tomorrow by many of the johnny come latelies who didn't sell today. it's not too late to bolt. you might ask, why bother, why do anything at all but sell? why not let everything come down huge? here is the issue. you're being given some incredible entry points that could be erased if the chinese cut rates to f

will listen to biogen and wellpoint which are pristine health care companies that go up when the rest of the market goes down. thursday we hear from three amazing tech companies that people don't realize are tech. they are called stealth tech in the get rich carefully, 3m, underarmor and colgate. if we're still down by thursday, look to the stocks as places to deliver good numbers. unlike today we still haven't discounted the negative news, by next thursday we should be less emotional. today was very emotional. these are stocks that could shoot higher if the market once again is willing to differentiate among stocks by then between the good, bad and, yes, the ugly. it doesn't feel like it on a day like this. eventually we do reach a point where dimaggio can get hot again. and if we have four straight session that's are horrendous going into friday, you may have to be ready to buy stocks no matter what because it would be so oversold. i'm suggesting considering abbvie. a terrific spinoff from abbott labs. if you're bearish about global growth, weyerhaeuser if you think the interest rat

pdl, it's not biogen, we have exxon mobile when i recommended. i'm not keen on tobacco.n't have both of these. that's not going to work. i know you want yield and you feel like yield should be the thing here. i'm going to send you to clorox. and that, ladies and gentlemen, is another round of am i diversified. no matter what, people can count on me to get the job done. so, when my prostate cancer returned, my doctor told me that this time can be different with provenge, a personalized treatment that lets me count on my own body to fight back. provenge is clinically proven to help extend life in certain men with advanced prostate cancer by taking your own blood cells and reprogramming them to jump-start your immune system, so it can attack your prostate cancer. provenge can cause serious reactions including those resulting from the infusion, and stroke. severe but infrequent infusion reactions include chills, fever, fatigue, weakness, breathing difficulties like shortness of breath, decreased oxygen and wheezing, dizziness, headache, high blood pressure, muscle ache, naus

players like glaxosmithkline, sanofi and biogen. i find this getting attractive.t's broken. all right. how about jazz pharma? a more established player, period of timable, the stock trading at an amazing 17 times next year's earnings despite having a 19% long-term growth rate. right now, jazz gets roughly 70% of the sales from an orphan drug for a rare type of narcolepsy that can sell for as much as $97,000 a year. this is patented, protected unbelievably. doesn't expire until 2019. on of that is sleep apnea drugs in the pipe. also a drug for acute lymphoblastic leukemia. the body rejects transplanted tissue, this one in phase 3, could be a big deal. last but not least, in december, jazz bought gentium for post stem cell transplant patients. this has been approved in europe, should be launched over here sometime this quarter. thing about jazz here, it's being viewed as a takeover candidate. remember how parago bought elan boy, that stock went up even though people didn't believe in it other than "mad money." the lower the stock goes, the more i like it. counterint

. >> that's from biogen sis. >> emails back and forth and lot more evidence than one guy. >> rodriguez of money and it wasn't for his personality or looks. >>. no you should be able to cross-examine the witnesses against you. >> i agree like boss. you can't let him answer questions for major league baseball. >> you say he has a threat of a case. you say he has no case. >> no. >> octomom, 14 kids, l.a., totally irresponsible. the woman is not very intelligent in my opinion. she is now charged with welfare fraud goifl. >> that's a problem. actually three counts total. two counts of perjury by false application for aid, one count of aid by misrepresentation. basically what it amounts to is that she failed to disclose income and royalties in the beginning of the year that she made that would have exceeded it. when you have 14 children. >> she made a porn movie or something. >> she actually made one by herself and she won an award for it i'm not sure who else. >> golden globe was it? that was on the other night. did you guys see her there was she arrested? >> not arrested. bail, 25 k. heari

we have celgene, biogen down more than 2% today. seems like investors are trying to sell some of their winners and we all know biotech has been one of the winning sectors in 2013. lastly, one of the big losers in tech is cisco. jpmorgan downgrading that stock to underweight citing its excessive valuation as well as weakness in emerging markets. back to you. >> thank you very much. >>> over the past week, cnbc has been warning of emerging problems on the horizon. those problems really popped up last week. we learned more about them over the weekend. today, they are the talk of wall street and global finance. michelle caruso-cabrera, sara eisen are here to explain different facets of exactly what's going on and why everything is so interconnected and why everyone is so bloody nervous. we begin in china, michelle. we use this as the definition of the problem, problem number one, a wager -- major wealth management product that's a fast growing financial product in china that invests in things considered risky over there, like real estat

couple of picks here, goldman says amgen and regeneron and deutsche bank says biogen, which actuallyted earnings and that stock is a big nasdaq winner. >>> sex sells pretty much anything, including watches, it turns out. robert frank? >> indeed. turns out there is a secret world of wealthy collectors of erotic watches, watches filled with diamonds, gold and some very interesting movements. we will give you a peek after the break. [ tires screech ] [ car alarm chirps ] ♪ [ male announcer ] we don't just certify our pre-owned vehicles. we inspect, analyze, and recondition each one, until it's nothing short of a genuine certified pre-owned mercedes-benz for the next new owner. [ car alarm chirps ] hurry in to your authorized mercedes-benz dealer for 1.99% financing during our certified pre-owned sales event through february 28th. >>> watch the dow there, folks. watch the dow, down 145 ahead of the fed. new episode of "secret lives of the super rich" at 9:00 p.m. eastern on cnbc. robert frank here with a sneak peek. erotic watches. >> peek is right. tonight we will show you some obscene

it's biogen leading the charge these days. on down days like today, you need to be looking for opportunities where you can find them. i'm talking about themes for 2014. they are making their minds up now, people, about where to place their bets. i need you in before those bets are made. "mad money" will be right back. >> coming up, secret ingredient? chicken, biscuits, and a plan to double its restaurant footprint in the u.s. does popeyes have the right recipe for a soaring stock price? cramer talks to the ceo an fresh off today's big announcement from the company. >>> and later, follow the money? when wall street big wigs pay special attention to a stock, investors tune in. but when big money moves into an investment you own, how do you play it? cramer's got the move. >>> plus, love logistics? it's been a bumpy road for u.p.s. after holiday mishaps. will this bitter blizzard be the next blow? or is it finally turning a corner. cramer's tracking what ground can do for you, just ahead. all coming up on "mad money." [ male annou

in 2013, four of the top six biggest gainers in the s&p health care index were biogen, vertex pharmaceuticalsween 77% to 115% on the year. traders are looking for volatility and opportunities. they still look towards these biotech stocks that are very up and down. look at intercept pharmaceuticals which soared over 500% last week on some positive test results for a liver drug. still, though, in 2014, it's the older, more established gains that are getting more attention. at least for now, they seem to be doing pretty well. >> thank you very much. let's transition to morgan brennan, who has been looking at which companies might be the next big breakout stars in biotech. >> so first a little background. the fda has four special high priority pipelines for drugs that could potentially be groundbreaking. here's where it gets interesting. the approval rates tend to be higher for drugs in these pipelines. for example, the fda's first cycle approval rate for drugs that receive priority review in 2013 was just about 100%. drugs that weren't in priority review, roughly 50% rate. that's looking at fda

biogen, among others, leading the nasdaq 100 higher and speaking of health care, you got to take a look at intuitive surgical. intuitive surgical shares, the best performing stock on the nasdaq 100 after its preliminary fourth quarter revenue beat street estimates. then switch over to tech, because tech is the best performing s&p sector providing market leadership. google, expedia, apple, yahoo! broad-based gains in tech. tech is a sector favored to move higher in a rising rate environment. lastly, social media, those stocks have had a couple volatile days. we are seeing facebook, twitter among others posting gains. sue? >> thank you very much, seema. >>> the trading action here, we are just off the highs of the trading session but the big event in today's trading session is two hawks on the fed are making comments. richard fisher will make comments shortly but mr. plosser has made some comments and is talking about perhaps aggressive moves on interest rates in the near future. i am very surprised this market has been able to hold on to its advances. >> remember yesterday, there were co

biogen was among the big winners. have a look at the start. the doubled last year. our investors right to be so optimistic? let's ask the ceo. that you are excited about? talk to us about your drugs, the prospects. especially in this new world of obamacare. year for us. great they did very well. this is done extremely well. well.been doing extremely we hope to have the same one in europe. we have three others that we hope to get approved. basically, for new drug launches including a lot of data on our developing pipeline. there is phase two data on a number of compounds for very important diseases. >> is a getting harder to win drug approval? a reputation for being tough or in some cases than the fda. what is your outlook? >> they have gotten somewhat more stringent. i don't think that it is any harder than it used to be. i think the challenge is to demonstrate the value of the new drug. justify the prices that they need. >> from a profitability standpoint, what is the big difference for a drug in europe or in the u.s.? >> joint prices are lower in europe. in the u.

. >> we haven't mentioned biogen, it's down, and 224 beats 228.g sales doubled has not moved to europe yet and that stock has tripled in the past two years. >> a revolutionary drug but there's some chatter, my friend, i'm seeing some -- a guy who writes for the street, talking about how maybe some of this is stocking. they stock and so, therefore, those numbers don't look as good. biogen was up very big ahead of this launch which is never a good sign. >> electronic arts continues to boggle the mind. they did beat estimates by 126. revenue was shy. lowers its 2014 revenue forecast and one of the big gainers today. >> we got an upgrade basically saying merrill goes hold to buy saying the next generation industry has great growth. i've been talking to take-two that also has, you know, a substantial business from grand theft auto. these are -- these are stocks that -- grand theft auto and take-two and a value stock and you know what happens. >> tupperware which actually has a relatively robust or had a robust business in turkey. misses, but one of the

we'll get results from biogen, idec, dow chemical and jet blue. after the bell we'll heard from facebook, qualcomm, los angeles sands. >>> revenue was the weak link citing a slowdown for alibaba. we'll tell you more right after this. opportunities aren't always obvious. sometimes they just drop in. cme group can help you navigate risks and capture opportunities. we enable you to reach global markets and drive forward with broader possibilities. cme group: how the world advances. >>> sainsbury appoints a new ceo to take over in july 2014. and in his fifth state of the union address, president obama takes a go it alone approach to pushing through economic reform. >>> okay. still with us is julie coronado. what did you make of the state of the union address and these ideas on minimum wage? what impact might, you know, raising it again. what impact might that have? >> well, i'm going to struggle to not be depressed by the state of the union. i think the good news in american politics is it's not as contentious as it was before. but if that's a policy

. >> carl, how about another biotech company, biogen is going to develop medicines for blood disordersest goals are met, both companies are up on the news. but sangamo is up big move because of the diseases and their cures, carl, back over to you. >>> 10:30 on the nose on the east coast and let's get to sharon epperson for inventories on nat gas. >> the latest report from the energy department said natural gas supplies in the last week fell by 157 million btus -- not btu, bcs, billion cubic feet. 157 decline is the number here from the energy department and that is greater than expectations. a lot of analysts were looking for a decline somewhere around 150 billion cubic feet. we are looking at natural gas futures prices that have come off the lows of the session. we saw the low of $12.04 a significant drop from last month when natural gas hit a 2 1/2-year high above the $4.50 mark. keep in mind we are looking at temperatures that will finally start to warm up a bit over the next week or so. that is what traders have been focused on in terms of the weather forecast going forward and tha

. >> the founder of the biogen sis clinic, anthony boesch, he gave his story on "60 minutes."njected a-rod with steroids and told him how to beat the system. >>> the final four is now set. the broncos clinch from spot with a win over the chargers. peyton manning was solid in this one, threw 2 touchdowns in the first half. the broncos held off a late rally to beat the chargers, 24-17. in the nfc, the 49ers beat the panthers to punch their ticket to their third straight nfc title game. colin kaepernick leading the way for san fran. he is going to get in the end zone. he mocks cam newton's touchdown celebration. the old superman. the niners ended up winning it, 23-10. >>> here is your schedule for the championship sunday. broncos and patriots going to square off at 3:00 p.m. eastern, manning versus brady, round 156789 the third time they are going to face off in the afc championship. that game followed by round three between the niners and seahawks. winners will be in the super bowl. >> i hope seattle will. >> hopefully, it will be exciting. >> yesterday was kind of -- >> i know.

upheld the majority of a 211-game suspension that he received last august for his connection to the biogen the nfl's fight off the field, first, a fan sues over high price super bowl tickets and now a major settlement over player concussions could fall apart. >>> plus, christie's crisis, will the bridge crisis be a simple traffic jam or a potential roadblock to a potential 2016 nomination? own . own . it's a stationery and gifts store. anything we purchase for the paper cottage goes on our ink card. so you can manage your business expenses and access them online instantly with the game changing app from ink. we didn't get into business to spend time managing receipts, that's why we have ink. we like being in business because we like being creative, we like interacting with people. so you have time to focus on the things you love. ink from chase. so you can. over the pizza place on chestnut street the modest first floor bedroom in tallinn, estonia and the southbound bus barreling down i-95. ♪ this magic moment it is the story of where every great idea begins. and of those who believed they

biogen swinging between losses and gains.t did have a little bit of a cautious guidance which worried analysts. coming you have after the bell, a big day for some nasdaq movers and shakers. qualcomm is the big one. it is lower ahead of earnings after the bell. the big reason is apple is one of its big companies. one of its being customers. so everyone waiting to see how the apple results may play out into qualcomm's results. and, of course, you have to talk about facebook. zuckerberg is taking center stage with his earnings report after the bell. all the talk about facebook these days has been whether the site is losing cool, whether teens are still coming there, is user engagement still high. those are key metrics investors will be focusing on. the hot word when coming to tech stocks, mobile, mobile, mobile. can facebook still post the mobile sales which it has been doing but is that uptrend still working in its favor? back to you. >> you know, sheila, do you think that qualcomm could be the bigger deal even than a facebook

the former chief of biogen sis telling "60 minutes" he personally delivered and injected rodriguez with banned substances. >> alex is scared of needles. so at times he would ask me to inject. >> you've injected him? >> yes. >> personally? >> yes. >> reporter: an arbitrator has banned a-rod for 162 games, the entire season. but a-rod is not done yet saying "have i been clear i do not hughes performance enhancing substances. >> i would give rodriguez the same advice i gave years ago, just fess up. >> reporter: rodriguez and other players were suspended last year after it was found then used performance-enhancing drugs. >> why he would continue to fight, no one knows. >> reporter: rodriguez says he still plans to travel to tampa for spring training. whether he'll be back for 2015 will be up to the yankees. >> unfortunately this is part of baseball. this is part of baseball. when you ask these guys to play a hundred plus games back to back, jump on a plane, get off a plane, all these road trips, their bodies break down. this has always been part of the game. >> i think a lot of people would

last night the found of the biogen esis speak publicly for the first time. >> he went to study the productstance and dosages. because he wanted to achieve all his human performance or in this case, sports performance objective and the most important one was the 800 home run club. which was only going to have one member, alex rodriguez. my approach to all this -- i'll stand by it now and i'll stand by it forever -- was you're going to do this, let me show you how to do this and let me educate you, and let's do it the right way. sure, let's not get caught while we're doing this. >> that is anthony bosch who runs the biogenesis clinic and did that interview with "60 minutes" and said he gave a-rod a program and -- >> night cream. >> therefore he passed all of the major league baseball tests and what a-rod hangs his hat on. you don't have a positive test to me. he admitted he did steroids in 2003 but nothing after 2003 and he is now saying this is not right, i should be able to play next year. he has ripped bosch and major league baseball and a lot of money at stake. >> now he is really throwi

here it is gilead, kind of a theme, biogen, a theme.s up 3%. >> nothing happened in gilead. >> it has $125 billion market value. that's correct. $125 billion. it's only $30 billion less than merck. >> merck doesn't have -- >> $25 billion less than merck. >> merck does not have the kind of momentum. i mentioned gilead in "get rich carefully" my book, it's one of the great stocks to watch. i do not think there's cause and effect. it would be like megalomania. and the stocks go up and go up and i search for news and there is none. because they're charmed. >> speaking of charmed, textron is up 35% since mid-october. they beat by a penny. revenue nice change in pace was actually above consensus. although a cautious view for the year there's a sense that this beechcraft deal will add to earnings at least in 2015. >> aerospace is so, so red hot. people were critical of herb greenberg you mentioned ibm 20 for 20 so to speak, but if you look at boeing, boeing's got a 20-year plan. and it's right. i mean, aerospace has a 20-year plan because you

among the stocks to keep an eye on today, biogen, that is 6 cents better than the street was expectingng the estimates, as well. >>> coming up, how close is bitcoin to full regulation? right now, some say it is still the wild, wild west. we can talk about that issue when we return. hi, are we still on for tomorrow? tomorrow. quick look at the weather. nice day, beautiful tomorrow. tomorrow is full of promise. we can come back tomorrrow. and we promise to keep it that way. driven to preserve the environment, csx moves a ton of freight nearly 450 miles on one gallon of fuel. what a day. can't wait til tomorrow. [ car alarm chirps ] ♪ [ male announcer ] we don't just certify our pre-owned vehicles. we inspect, analyze, and recondition each one, until it's nothing short of a genuine certified pre-owned mercedes-benz for the next new owner. [ car alarm chirps ] hurry in to your authorized mercedes-benz dealer for 1.99% financing during our certified pre-owned sales event through february 28th. >>> welcome back to "squawk box." backers of bitcoin gathering in new york for hearings on the dig